Nanjing Wellman Pharmaceutical Research Institute

Nanjing Wellman Pharmaceutical Research Institute is a specialized pharmaceutical R&D organization based in Nanjing, China, serving as a primary innovation hub for the Wellman Pharmaceutical Group. The institute is widely recognized for its expertise in developing combination anti-infective therapies, specifically focusing on pairing beta-lactam antibiotics with beta-lactamase inhibitors to combat bacterial resistance. It has successfully developed and commercialized a variety of first-in-China combination drugs, including Piperacillin Sodium and Sulbactam Sodium. Beyond its core strength in antibiotics, the institute's research portfolio extends to cardiovascular, metabolic, and oncological therapeutic areas. Its capabilities span the entire drug development spectrum, including chemical synthesis, advanced formulation technology, and regulatory affairs.